BlackRock Fund Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

BlackRock Fund Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$123M	Buy	1,126,612 +79,477	+8%	+$8.85M	0.02%	1047
2016 Q3	$127M	Buy	1,047,135 +47,834	+5%	+$6.45M	0.03%	896
2016 Q2	$141M	Sell	999,301 -527,855	-35%	-$77.8M	0.03%	726
2016 Q1	$199M	Buy	1,527,156 +47,265	+3%	+$5.88M	0.05%	493
2015 Q4	$208M	Sell	1,479,891 -103,803	-7%	-$14.4M	0.05%	464
2015 Q3	$210M	Buy	1,583,694 +66,884	+4%	+$11.5M	0.05%	400
2015 Q2	$267M	Buy	+1,516,810	New	+$272M	0.06%	337
2015 Q1	–	Sell	-1,336,178	Closed	-$219M	–	3770
2014 Q4	$219M	Buy	1,336,178 +21,315	+2%	+$3.54M	0.05%	403
2014 Q3	$211M	Buy	1,314,863 +52,170	+4%	+$8.02M	0.06%	363
2014 Q2	$186M	Buy	1,262,693 +47,463	+4%	+$6.58M	0.05%	424
2014 Q1	$169M	Buy	1,215,230 +64,368	+6%	+$9.69M	0.05%	469
2013 Q4	$146M	Buy	1,150,862 +39,822	+4%	+$4.12M	0.04%	558
2013 Q3	$102M	Buy	1,111,040 +100,866	+10%	+$8.14M	0.03%	727
2013 Q2	$69.4M	Buy	+1,010,174	New	+$61.7M	0.03%	935

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BlackRock Fund Advisors's JAZZ Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 7.6% in Q4 2016, buying an estimated $8.85M and bringing the position to 1,126,612 shares worth $123M. The position accounts for 0.02% of the portfolio, ranked #1047.

BlackRock Fund Advisors first reported a position in JAZZ in Q2 2013 and has held it in 14 quarters since. The position peaked at $267M in Q2 2015. 295 funds tracked by Wall St. Rank hold JAZZ as of Q4 2016.

BlackRock Fund Advisors held 1,126,612 shares of Jazz Pharmaceuticals worth $123M as of Q4 2016.
BlackRock Fund Advisors bought 79,477 Jazz Pharmaceuticals shares in Q4 2016, an estimated $8.85M.
Jazz Pharmaceuticals made up 0.02% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1047 holding.
BlackRock Fund Advisors first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 14 quarters since.
BlackRock Fund Advisors's Jazz Pharmaceuticals position peaked at $267M in Q2 2015.
295 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.